- Home
- LSEA vs PRQR Comparison
LSEA vs PRQR Comparison
Compare LSEA & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEA
- PRQR
- Stock Information
- Founded
- LSEA 2013
- PRQR 2012
- Country
- LSEA United States
- PRQR Netherlands
- Employees
- LSEA N/A
- PRQR N/A
- Industry
- LSEA Homebuilding
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- LSEA Consumer Discretionary
- PRQR Health Care
- Exchange
- LSEA Nasdaq
- PRQR Nasdaq
- Market Cap
- LSEA 300.4M
- PRQR 309.5M
- IPO Year
- LSEA N/A
- PRQR 2014
- Fundamental
- Price
- LSEA $7.60
- PRQR $1.63
- Analyst Decision
- LSEA Buy
- PRQR Strong Buy
- Analyst Count
- LSEA 4
- PRQR 6
- Target Price
- LSEA $13.75
- PRQR $8.50
- AVG Volume (30 Days)
- LSEA 340.2K
- PRQR 448.8K
- Earning Date
- LSEA 04-30-2025
- PRQR 03-13-2025
- Dividend Yield
- LSEA N/A
- PRQR N/A
- EPS Growth
- LSEA N/A
- PRQR N/A
- EPS
- LSEA 0.47
- PRQR N/A
- Revenue
- LSEA $1,550,337,000.00
- PRQR $20,235,014.00
- Revenue This Year
- LSEA $4.04
- PRQR $39.44
- Revenue Next Year
- LSEA $5.27
- PRQR N/A
- P/E Ratio
- LSEA $15.86
- PRQR N/A
- Revenue Growth
- LSEA 28.13
- PRQR 196.41
- 52 Week Low
- LSEA $6.54
- PRQR $1.59
- 52 Week High
- LSEA $14.91
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- LSEA 50.77
- PRQR 26.44
- Support Level
- LSEA $7.13
- PRQR $1.78
- Resistance Level
- LSEA $7.47
- PRQR $1.87
- Average True Range (ATR)
- LSEA 0.35
- PRQR 0.13
- MACD
- LSEA 0.07
- PRQR -0.03
- Stochastic Oscillator
- LSEA 84.30
- PRQR 4.69
About LSEA Landsea Homes Corporation
Landsea Homes Corp is a homebuilding company. It designs and builds homes and sustainable master-planned communities in some of the nation's desirable markets. The company's segments include Arizona, California, Florida, Metro New York, and Texas. It derives a majority of revenue from home sales in Florida.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.